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in the mucosal lining of the upper-aerodigestive tract. These precancerous cells contain cancer-
associated genomic changes and cause primary tumors and local relapses. Therapeutic strategies to 
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variable molecular basis of the vulnerabilities in tumor and premalignant cell lines and found indications 
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comparable responses as fully transformed HNSCC cells.
Head and neck squamous cell carcinomas (HNSCCs) arise in the mucosal lining of the upper-aerodigestive tract 
and account for around 5% of the total cancer incidence1,2. he main risk factors for head and neck cancer are 
smoking and excessive alcohol consumption, infection with a high-risk type of the human papillomavirus (HPV), 
or genetic predisposition such as Fanconi anemia (FA)2. FA is characterized by congenital abnormalities, pro-
gressing anemia, and cancer predisposition, particularly of oral cancers. hese tumors are diicult to manage as 
FA-patients are sensitive to cross-linking agents such as cisplatin, hampering clinical management of tumors, and 
for these patients surveillance and prevention is key.
Tumors in the head and neck region develop in premalignant mucosal changes, large epithelial areas charac-
terized by cancer-associated genetic changes, also referred to as “ields”. hese precancerous ields can be centim-
eters in size, and are oten macroscopically invisible. A minority manifests as visible mucosal lesions known as 
leukoplakia or erythroplakia, which occur with a prevalence of around 0.1–0.2% for leukoplakia3, and 0.02–0.2% 
for erythroplakia4. Every year, 1–2% of the leukoplakia lesions progress into cancer, and erythroplakia lesions 
inevitably progress.
Despite the occurrence and prevalence of these visible lesions, the large majority of head and neck cancers 
develop de novo. In resected tumor specimen, however, preceding premalignant changes can be oten identiied 
in the surgical margins by either microscopic detection of dysplasia or by genetic analysis5. When these ields are 
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incompletely removed ater tumor excision, they oten lead to a local relapse2,6. Moreover, independent ields may 
exist that did not undergo malignant transformation yet, and may cause second primary tumors7.
hese premalignant ields are di cult to manage clinically. Small visible lesions can be excised or treated using 
laser. Unfortunately, eicacy is limited as lesions frequently recur and subsequently undergo malignant transfor-
mation, or tumors may develop elsewhere. Larger lesions and ields that are not visible cannot be treated yet2–4. 
When tumors occur, treatment is obviously focused on the index tumor, which may comprise of surgical resec-
tion with or without post-operative (platinum-based chemo-) radiotherapy, or upfront chemo-radiotherapy2,8. 
Despite these invasive treatment protocols, local relapses frequently occur even when the surgical margins are 
histologically tumor-free, and oten develop from ields that stayed behind unnoticed2. Improvement of therapy 
protocols is therefore necessary to treat not only the tumors more efectively, but also these premalignant ields. 
Targeted treatment approaches seem an attractive option, however, targetable mutations in oncogenes rarely 
occur in head and neck (pre)cancer, hampering the identiication of suitable drug targets5,9. A second problem 
in designing novel targeted chemopreventive strategies is the lack of in vivo models. In vitro premalignant oral 
cell models have been developed, but these do not form detectable premalignancies in in vivo xenograt models, 
complicating preclinical investigations5.
Exploration of both synthetic and collateral lethality may form alternative strategies for targeted therapy 
approaches. Cells that harbor mutations in tumor suppressor genes may become vulnerable for functional losses 
of other genes or pathways. As an example, frequent inactivation of CDKN2A and over-expression of D type cyc-
lins point towards cell cycle aberrations that might cause replication stress and genomic instability, and provide 
an entry point for targeting strategies through synthetic lethality. Alternatively, HNSCC cells are characterized 
by frequent chromosomal aberrations that result loss of chromosomal loci associated with inactivation of tumor 
suppressor genes9. With the loss of a locus containing a tumor suppressor gene, neighboring genes are oten 
afected as well, which causes homozygous or heterozygous deletions of these passenger genes10. Loss of some of 
these passenger genes may cause sensitivity to inhibition by siRNAs or drugs, or the cell becomes fully dependent 
on the paralogue of the (partially) lost gene. hese vulnerabilities are named collateral lethality, and these genes 
can be explored as therapeutic targets10.
To investigate new therapeutic approaches to target the invasive cancers, we previously performed 
genome-wide RNA interference (RNAi) screens11, and a panel of over 300 tumor-lethal siRNAs were identiied. 
In the current study, we used a custom library of these lethal siRNAs to further investigate the vulnerabilities of 
both cancer and premalignant cells compared to normal primary cells.
Results
ƤǤ We constructed a custom siRNA SMARTpool library (Fig. S1a) based 
on hit selection in previously performed array-based genome-wide siRNA screens in two tumor cell lines. he 
library consisted of 319 siRNAs targeting genes that were found to be essential in these initial two tumor cell 
lines11. Rescreening of the custom library in the originally screened HNSCC cell line revealed conirmation of 
85% of the hits12, indicating the accuracy of the approach and these data were also included in this study as 
a reference 12. Here, we extended the cell line panel with three HPV-negative and four HPV-positive HNSCC cell 
lines, and in addition four HPV-negative HNSCC cell lines established from head and neck tumors in Fanconi 
anemia (FA-)patients. We further included primary non-transformed oral ibroblasts of two healthy donors 
and one FA-patient, to identify tumor-speciic lethality (Table 1, Fig. S1b). Normalized Log2 transformed data 
points demonstrated an accurate separation of the positive (e.g. siUBB, Ubiquitin B, in red) and negative controls 
(siCONTROL#2, in blue) (Fig. 1a). As expected the majority of the pre-selected siRNAs (in black) had a lethal 
efect in most cell lines. To identify the siRNA SMARTpools that induced a relevant decrease in cell viability, 
Cell line Type Site
Doubling 
time (h)
Method of 
transfection
Transfection 
reagent
Cells per 
well
Volume reagent 
well (µL)
Fibroblasts #50 Primary ibroblasts Uvula 32 Reverse RNAiMax 2000 0.05
Fibroblasts #54 Primary ibroblasts Uvula 20 Reverse RNAiMax 2000 0.06
Fibroblasts VU-1678 Primary ibroblasts — 47 Reverse RNAiMax 2000 0.05
VU-SCC-120 (reference) HPV-negative tumor Tongue 20 Forward DharmaFECT #1 1000 0.03
VU-SCC-OE HPV-negative tumor Floor of mouth 30 Reverse DharmaFECT #1 5000 0.08
UM-SCC-11B HPV-negative tumor Larynx 22 Forward DharmaFECT #1 2000 0.035
UM-SCC-22B HPV-negative tumor Hypopharynx 23 Forward DharmaFECT #1 4000 0.1
VU-SCC-1131 FA-derived tumor Floor of mouth 24 Reverse RNAiMax 2000 0.02
VU-SCC-1365 FA-derived tumor Mouth mucosa 27 Reverse RNAiMax 4000 0.06
CCH-FAHNSCC-2 FA-derived tumor — 15 Reverse RNAiMax 3000 0.04
VU-SCC-1604 FA-derived tumor Tongue 30 Reverse RNAiMax 2500 0.03
UM-SCC-47 HPV16-positive tumor Lateral tongue 27 Forward DharmaFECT #1 5000 0.1
VU-SCC-147 HPV16-positive tumor Floor of mouth 25 Reverse DharmaFECT #1 4000 0.1
UT-SCC-45 HPV33-positive tumor Oral cavity 28 Forward DharmaFECT #1 2500 0.14
UM-SCC-104 HPV16-positive tumor Floor of mouth 67 Reverse DharmaFECT #1 5000 0.11
Table 1. Overview of cells screened with the tumor-lethal library. - Unknown. FA Fanconi anemia. HPV 
Human Papillomavirus.
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median values per cell line were calculated and the cut-of for selection was set at a viability score of −0.5. Using 
this cut-of >99% of the negative controls were scored as negative and all positive controls were scored as positive.
Cluster analysis of median viability scores. Unsupervised cluster analysis of the normalized and trans-
formed median cell viability values did not reveal clear diferences between the FA patient-derived, HPV-positive 
and HPV-negative tumor cell lines (Figs. 1b and S1c). Instead, two main clusters were found, which seemed to 
correspond mainly to the number of hits identiied (<200 and >200; Fig. 1c). Within the cluster with <200 
essential genes, the primary ibroblasts formed a separate group. he separation into two clusters neither related 
to diferences in transfection reagent, nor to reverse or forward transfection, nor to cell doubling time12,13. Next, 
we assessed the number of identiied lethal siRNA SMARTpools per cell line (Fig. 1c). his number ranged from 
64 (ibroblast culture) to 273 (UM-SCC-22B) with a median of 222. Most prominent were the low numbers of 
lethal siRNAs in the primary ibroblasts, less than 100 siRNAs were lethal for all three donors. he diference in 
lethal hits between primary ibroblasts and tumor cells reveals an exploitable window for selective tumor cell 
targeting therapies.
Collateral lethality analysis. he concept of collateral lethality associates genomic aberrations in tumor 
cells to speciic vulnerabilities of gene interference in these cells. We hypothesized that some identiied lethal hits 
within our rescreen could be explained by a heterozygous loss or ampliication of the related chromosomal locus. 
herefore, we adapted and applied an integrated analysis as previously described by Menezes et al.14 of the cell 
line DNA copy number (CN) data per chromosome arm15 and the siRNA lethality data per cell line. Aberrations 
of chromosome arms 3p, 7p, 10p, 8q, 9q and 18q demonstrated signiicant associations with speciic siRNA vul-
nerabilities of genes located at these loci (Table 2). We identiied positive partial correlations between siRNAs and 
losses at chromosome arms 3p, 10p and 18q (Z-score > 3) and negative partial correlations between siRNAs and 
gains at chromosome arms 7p, 9q and 8q (Z-score < −3). Associations with gains and ampliications may point to 
collateral gene addictions, while associations with losses indicates a more classical collateral lethality. Loss of one 
copy of a tumor suppressor gene by a (partial) chromosomal loss, likely reduces expression of neighboring genes 
and may increase vulnerability to siRNAs targeting these.
Four candidate genes with a positive correlation (RPSA, RPL14, RPL17 and PSMD6) and one with a negative 
correlation (RPS20) were further investigated by knockdown of expression of these genes with the relevant siRNA 
SMARTpool. All these genes, except proteasome subunit PSMD6, encode for ribosomal proteins. CN data of 
these speciic genes revealed that the viability ater transfection indeed positively correlated to losses for RPSA, 
RPL14, RPL17 and PSMD6, with p-values of 0.01, 0.04, 0.03 and 0.04, respectively (Fig. 1d–h). hese data indicate 
that collateral lethality by targeting neighboring genes could indeed explain a number of tumor-speciic hits and 
seems to form a genuine basis for hit selection.
Hit selection in cancer and precancer cell lines. he knockdown efect of many genes was tumor cell 
line-speciic, indicating a large variation in vulnerabilities and limiting applicability of potential inhibitors as a 
panHNSCC treatment strategy. We therefore mined our rescreen siRNA data for shared vulnerabilities across 
multiple tumor cell lines (Table S2). Our criterion of a panHNSCC-lethal hit was arbitrarily chosen as a viability 
score ≤ −0.5 in at least 24 out 36 tumor cell line replicates. Additionally, genes were classiied as ‘core itness’ 
genes16 in both tumor cells and normal cells, when knockdown was also lethal in more than 6 out 9 ibroblast 
replicates. In total, 197 out of 319 siRNA SMARTpools met the criterion ‘panHNSCC-lethal’, whereas 50 of these 
siRNA SMARTpools were also lethal in six or more ibroblast replicates. his resulted in 147 panHNSCC target 
genes and 50 core itness genes (Table S2).
KEGG pathway analysis using DAVID revealed that the 147 tumor-speciic siRNAs can be classiied in seven 
functional subgroups, whereas the 50 core essential genes were mainly ribosomal (Fig. S2a,b)17. For further 
selection of the 147 hits we mined a ‘drug to gene-interaction’ database and this revealed 34 druggable genes 
(Table S3)18.
To further select candidate siRNA SMARTpools that target premalignant cells as well, we interrogated and 
re-analyzed the data of the previously screened precancerous cell line VU-preSCC-M3 with the same 319 siR-
NAs12. his revealed that 22 genes out of the 34 druggable essential genes in cancer cells are also essential in 
precancerous cells (Table S3). he top ive lethal siRNAs in VU-preSCC-M3 were directed against KIF11, RRM1, 
NHP2L1, WEE1 and SF3B1, and all showed efect in at least 9 of 12 tumor cell lines (Table S3). KIF11 encodes 
for a mitotic spindle protein and was previously identiied to be tumor-lethal in HNSCC11. RRM1 is involved 
in deoxynucleotide synthesis and cell cycle progression. It is also a cellular target for a chemotherapeutic agent, 
gemcitabine. Interestingly, NPH2L1 and SF3B1 are splice factors and both cancer and precancerous cells displayed 
an increased dependency on splicing19.
he most promising hit for clinical implication to target premalignant squamous cells seemed Wee1-like 
kinase (WEE1), a key component in cell cycle control that regulates the activities of cyclin bound CDK1 and 
CDK2. he Wee1 inhibitor Adavosertib (formerly known as MK-1775 and AZD1775) is currently under inves-
tigation in clinical trials to treat solid tumors and seems promising for ovarian and head and neck cancer20,21. 
We therefore investigated the potential of Wee1 inhibition as chemopreventive strategy for mucosal precancer, 
included HNSCC tumor cell lines, and also related the indings to ovarian cancer cells as reference.
ͷȋȌǤ All tumor cell lines showed a decreased cell viabil-
ity with a value ≤ −0.5 upon WEE1 knockdown, except VU-SCC-1604 (Table S3). Primary oral ibroblasts also 
responded slightly to WEE1 knockdown, but did not reach the cut-of.
We next deconvoluted the siWEE1 SMARTpool in several cell lines to confirm the re-screening results 
(Fig. 2a–e). Two out of four individual siRNAs had similar efects on the viability of VU-preSCC-M3 and HNSCC 
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Figure 1. Screening of 319 tumor-lethal siRNAs on a panel of cancer, premalignant and normal primary cell 
cultures and the exploitation of collateral lethality. (a) Distribution of all siRNAs is shown. he x-axis represents 
the viability score (normalized log2 transformed values). he y-axis represents the density score of the siRNAs. 
In red, all positive controls (siUBB) are shown, and in blue all negative controls (siCONTROL#2) are depicted. 
An accurate separation between the controls was obtained. he black line represents all 319 siRNAs, which were 
considered lethal at the viability score cut-of ≤−0.5. (b) Cluster analysis of the twelve re-screened HNSCC 
cell lines. he HPV-negative HNSCC lines are presented in red, in blue the HNSCC lines from Fanconi anemia 
patients, in yellow the HPV-positive HNSCC lines, and in green three non-transformed ibroblast cultures. 
he cluster analysis revealed no diferences between the cancer sub-groups. Most obvious are the low numbers 
of hits in the normal primary cells. (c) Number of lethal siRNA SMARTpools with a viability score of ≤ −0.5, 
per cell line. In all three non-transformed oral ibroblasts, less than 100 essential genes were found. (d–h) All 
screened cell lines were divided on the basis of genomic loss analysis in two groups; either the cell line was CN 
neutral, or had a heterozygous CN alteration of the bins where RPSA (d), RPL14 (e), RPL17 (f), PSMD6 (g) or 
RPS20 (h) are located. he group without aberrations displayed signiicant less reduction in cell viability upon 
knockdown of RPSA (two-sided t-test, p = 0.01), RPL14 (two-sided t-test, p = 0.04), RPL17 (two-sided t-test, 
p = 0.03) and PSMD6 (two-sided t-test, p = 0.04). For RPS20, no signiicant correlation was found between CN 
status (allelic gain) and siRNA viability.
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cell lines as the SMARTpool. In contrast, they did not afect the viability of primary oral ibroblasts, indicating a 
therapeutic window in line with the results from the siRNA re-screen. A near complete Wee1 protein knockdown 
was observed for the pooled siRNAs and siWEE1 #2 and #4 24 h post-transfection, whereas knockdown with 
siWEE1 #1 and #3 resulted in a slightly reduced protein level (Fig. 2f), an observation concordant with the siRNA 
transfection efects on cell viability (Fig. 2c).
To further validate the potential of Wee1 inhibition as a chemopreventive therapy, a panel of premalignant 
cell cultures was treated with Adavosertib, together with a panel of HNSCC and two ovarian tumor cell lines as 
reference, since ovarian cancer is known to be vulnerable to Wee1 inhibition in clinical studies20,22. he tested cell 
lines all harbored a TP53 mutation (Table S4). Primary non-transformed oral ibroblasts and keratinocytes from 
healthy donors served as toxicity controls to indicate a potential therapeutic window compared to premalignant 
and tumor cells. All HNSCC tumor cell lines and premalignant cells responded in comparable concentration 
ranges as the tested ovarian tumor cell lines OVCAR3 and SKOV3, or were even more sensitive (Figs. 3a–g and 
S2c–e). he tested primary oral cells did not respond to Wee1 inhibition, or at least at much higher concentra-
tions. Primary ibroblasts from two independent donors showed a remarkable biphasic response, which may 
suggest inhibition of a secondary target of Adavosertib afecting ibroblasts speciically. We could not determine 
the EC50-values of the ibroblasts due to this biphasic response. he tested primary keratinocytes did not show a 
biphasic response and the EC50-values were 10 to 100 times higher than the EC50-value of cell line UM-SCC-38 
(highest EC50) or UM-SCC-22A (lowest EC50), respectively (Fig. 3g). he therapeutic window between the pri-
mary keratinocytes on the one hand, and the squamous cancer and precancerous cells on the other, as well as 
the comparable responses in comparison to ovarian tumor cell lines are promising for clinical applications of 
Adavosertib in HNSCC and oral precancer.
Combination of Wee1 inhibition with γ-irradiation or PARP inhibition have been under investigation for 
other cancer types23–25. Despite reports of additive or synergistic efects in other tumor cell models, combin-
ing Wee1 inhibition with irradiation did not reveal an additional therapeutic efect for HNSCC cell lines. Also 
the combination of Adavosertib with the highly speciic PARP catalytic inhibitor and potent trapper of PARP1 
Talazoparib did not enhance therapeutic eicacy in HNSCC-derived cell lines (Fig. S3a,b).
Besides Wee1 and CDC25, Chk1 plays a key role in cell cycle control and regulation of CDK1 activity, and we 
wondered whether responses to Chk1 inhibitors correlate to those of Wee1 inhibitors. Although the cell line panel 
is small, no correlation was found between sensitivities to Chk1 inhibition with Rabusertib (LY2603618)26 and 
Wee1 inhibition (Fig. S3c; n = 6, Pearson’s correlation R = −0.04, p = 0.94), implying distinct regulatory mecha-
nisms. Furthermore, no correlation was found between cell line sensitivity to cisplatin treatment13 and Wee1 inhi-
bition (Fig. S3d; n = 8, Pearson’s correlation R = 0.63, p = 0.10), which suggests that patients who do not respond 
to classical chemo-radiation with cisplatin might be well treatable by Wee1 inhibitors (Fig. 3g).
 ?Ǥ In HNSCC cell cycle control is frequently abrogated at 
G1/S by somatic changes in CDKN2A, cyclin D1 and TP538. Premature S-phase entry causes replication stress 
and demands more precise S-phase control by Chk126 and control at G2/M. he complex of CDK1-Cyclin B 
is the key regulator of G2-to-M transition and onset of mitosis, and regulates to a lesser extent S-to-G2 tran-
sition27. Wee1 regulates CDK1 activity through Y15-phosphorylation, thereby preventing premature CDK1 
activation and mitotic entry. As most premalignant cells also have genetic changes in TP53 and CDKN2A5, we 
questioned whether precancerous cells face comparable problems in replication and cell cycle regulation as 
HNSCC cells, and respond comparably to Wee1 inhibition. herefore, we investigated cell cycle progression ater 
24 h of Wee1 inhibition (Figs. 3h–j and S3e). Both premalignant cell lines VU-preSCC-M3 and D19 showed an 
increased S-phase population ater 24 h of Wee1 inhibition, although VU-preSCC-M3 had an increase in repli-
cating S-phase (EdU-positive cells) and D19 in non-replicating S-phase (BrdU-negative cells). In fact, all tested 
HNSCC and OVCAR cell lines, except UM-SCC-22A and UM-SCC-14C, showed an increased population of 
non-replicating S-phase cells at baseline when compared to the premalignant cells, implying a more severe cell 
cycle disruption at baseline. Ater treatment, a majority of cell lines in this panel showed an S-phase increase 
(D19, VU-preSCC-M3, UM-SCC-22A, UM-SCC-14C, UM-SCC-11B, VU-SCC-120, UM-SCC-38 and SKOV3), 
Gene Location
RPSA 3p22.1
RPS20 8q12.1
RPL14 3p22.1
RPL17 18q21.1
PSMD6 3p14.1
PSMA2 7p14.1
SEC61G 7p11.2
HNRNPK 9q21.32
RPL30 8q22.2
RPL8 8q24.3
PRPF18 10p13
SNRPD1 18q11.2
Table 2. Collateral lethality.
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while two lines displayed a G1 increase (VU-SCC-096 and OVCAR3), which seemed to relate to sensitivity to 
Adavosertib as the latter two are less sensitive.
 ?Ǧ
and unsupervised entry of mitosis. Since Wee1 is a main inhibitor of CDK1, which controls mitosis, the 
molecular activation of a number of key regulators of mitosis was further investigated (Figs. 4a–d and S4a–c). 
Expression levels of CDK1 and its binding partner cyclin B1 (not shown) remained more or less stable upon 
Wee1 inhibition, although the large number of dying cells ater 24 h of treatment might have hampered interpre-
tation of the data. Upon treatment with 100 nM Adavosertib, the inhibitory phosphorylation of Y15 on CDK1 
decreased, conirming efective Wee1 inhibition. Furthermore, induction of DNA damage marker γH2Ax Ser139 
was observed in both premalignant cells and tumor cell lines ater Adavosertib exposure, indicating that the loss 
of Wee1 activity impacts replication stress and associated DNA damage, or impairs DNA repair signaling. Taken 
together, cancer cells that are in S-phase or in G2-phase, enter mitosis prematurely by Wee1 inhibition, which 
leads to mitotic failure, in line with the cell cycle distribution upon Wee1 inhibition.
Next, we investigated abnormalities in mitotic cells in precancerous VU-preSCC-M3 and HNSCC UM-SCC-
22A cells ater 48 h of Wee1 inhibition. Microtubules and spindle formation were visualized using α-Tubulin 
(green) and DNA was stained with DAPI (blue) (Fig. 4e,f). In untreated conditions, both premalignant as well 
as HNSCC cells showed normal bipolar spindles and chromosomal condensation during mitosis. Ater Wee1 
inhibition, the spindles showed abnormalities and the chromosomes failed to align in the metaphase plate. Both 
giant cells with fragmented DNA (arrows) and isolated DNA nuclei appeared frequently, indicating mitotic fail-
ure. Remarkably, upon treatment with 100 nM Adavosertib, we observed a signiicant increase in the spindle 
pole-to-pole distance in (pro-)metaphase cells, compared to untreated cells for both VU-preSCC-M3 (two-sided 
t-test, p = 0.007) and UM-SCC-22A (two-sided t-test, p < 0.0001) (Figs. 4g,h and S4d). his indicates mitotic 
arrest due to SAC-checkpoint activation, inward forces on the spindles due to DNA damage caused by Wee1 
Figure 2. siRNA validations of siWEE1. (a–e) Deconvolution of the SMARTpool in the four separate siRNAs 
all targeting WEE1 in (a) VU-preSCC-M3 (precancerous cell line in blue), (b) the primary oral ibroblasts (in 
green), (c) UM-SCC-22A, (d) VU-SCC-OE, and (e) VU-SCC-120 (all HPV-negative HNSCC lines in red). 
All graphs show the efect on cell viability upon knockdown compared to the negative transfection control 
used. Negative transfection control siCONTROL#2 was used for primary ibroblasts, UM-SCC-22A, and VU-
SCC-OE. Since toxicity was observed with siCONTROL#2 transfection in VU-preSCC-M3 and VU-SCC-120, 
siLUC and siHPRT1 were used, respectively, which were set at 100% cell viability. (f) he Wee1 protein levels 
were examined on Western blot and revealed a near complete knockdown for the siWEE1 SMARTpool and 
siWEE1 #2 and #4. siWEE1 #1 and #3 showed a reduced level of Wee1 protein expression 24 h post-transfection. 
Knockdown efects on Wee1 protein level correlated with the viability efects as found in Fig. 2c. Negative 
transfection controls siCONTROL#2 and siLUC were taken along for comparison with untransfected cells.
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Figure 3. Efects on cell viability and cell cycle distribution upon Wee1 inhibition with the clinically relevant 
inhibitor Adavosertib. (a–f) Line graphs representing the dose responses upon 72 h Adavosertib treatment 
are shown for premalignant cells (VU-preSCC-M3 (a) and D19 (b), in blue), HPV-negative HNSCC cell line 
UM-SCC-22A (c, in red), primary oral ibroblasts and keratinocytes (d,e, both in green) and ovarium cancer 
cell line OVCAR3 as reference (f, in purple). All graphs display the relative cell viability compared to untreated 
cells upon increasing concentrations of the inhibitor ater 72 h of exposure. Relative cell viability to untreated 
cells is shown for a serial dilution of Adavosertib (at logarithmic x-axis), and the viability of the untreated cells 
(presented as relative cell viability of 1) is imputed at 100 pM. A larger cell line panel is presented in Fig. S2c–e. 
(g) Overview of the EC50-values (µM) of all cell lines tested, except the ibroblasts. he purple lines represent the 
reference ovarian tumor cell lines and the green lines the EC50-values of the primary keratinocyte cultures. he 
majority of HNSCC and premalignant cells are equally or even more vulnerable to Adavosertib compared to 
both ovarian tumor lines tested. (h–j) Cell cycle distribution of precancerous cell lines VU-preSCC-M3  
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inhibition, and spindle exhaustion28–30. he treatment condition with 250 nM Adavosertib was already too toxic 
and did not contain enough (pro-)metaphases for further analysis.

We re-screened a previously identiied panel of siRNA SMARTpools that target essential genes in two cancer cell 
lines. We could conirm 62% of the previously identiied genes as essential in a large cell line panel of difer-
ent HNSCC subclasses, obtaining insight in possible new targets for therapy of precancerous cells, as well as 
HPV-negative, HPV-positive and FA-derived tumors11. Of the conirmed lethal siRNAs, 25% target core essential 
genes of which knockdown is also lethal for primary oral ibroblasts16, but 75% seem cancer cell-speciic indicat-
ing the opportunities for tumor-speciic targeting. However, broad application is complicated by the observation 
that responses varied considerably between cell lines. Although this likely relects the inter-tumoral heterogeneity 
of HNSCC31, it demands clinical development of inhibitors in parallel with companion diagnostic biomarkers for 
patient selection9.
Numerous novel candidate cancer genes have been identiied by the sequencing of over 500 HNSCCs by the 
TCGA consortium, which again stresses the inter-tumoral heterogeneity of the disease despite that it develops 
from just one cell type in one tissue9. Disappointingly, the sequencing eforts also demonstrated the lack of drug-
gable oncogenic mutations. Nonetheless, the many mutated genes as well as the multiple chromosomal aberra-
tions may form a source for druggable targets by synthetic or collateral lethality. We identiied many more lethal 
hits in the screened tumor cell lines than in the primary oral cells. he association of these essential genes with 
the genetic changes in these tumor cells suggest that collateral lethality does provide a novel strategy to identify 
vulnerabilities32. Upon the loss of a bona ide tumor suppressor gene through genetic aberrations, a neighboring 
passenger gene is oten homozygously or heterozygously lost as well. hese neighboring gene losses were consid-
ered futile, but in recent studies it has been demonstrated that the genes located at these loci may play important 
roles in a variety of key metabolic and regulatory functions, and the subsequent decrease in expression can be 
exploited as treatment strategy10,33,34. Further investigation of collateral lethal hits could lead to the identiication 
of future targets for therapy32.
Besides options for tumor treatment, we identiied gene targets for chemopreventive treatment of prema-
lignant changes. he number of targets for treatment of premalignant cells is relatively low, likely associated 
with the smaller number of genetic changes5,12. Nevertheless, there are promising candidates such as PLK112 and 
Wee1-like kinase as presented in this study.
Wee1 is an important negative regulator of CDK1, and critically for correct entry into mitosis at the end of 
G2-phase35. In a TP53 mutated background, Wee1 is thought to be involved in S-phase regulation as well through 
CDK2  phosporylation25. In our data, we noted ater Wee1 inhibition a variety of changes in cell cycle control, 
DNA damage, and abnormal mitosis. his clearly suggests a key role of Wee1 in HNSCC cells, and involvement 
of Wee1 in squamous (pre)cancer cell cycle regulation. Unexpectedly, responses to Adavosertib difered between 
primary keratinocytes and ibroblasts in vitro. It has been reported that Adavosertib targets the Yes tyrosine 
kinase with 2- to 3-fold less potency22. Others reported that Yes knockdown increases proliferation and migration 
in ibroblasts, potentially explaining the slight increase in viability in the tested ibroblasts36,37. Interestingly, we 
compared the sensitivity to Wee1 inhibition in a TP53 wild-type HNSCC cell line and ater TP53 CRISPR/Cas9 
knockout, and no diference in vulnerability was observed suggesting a somewhat more complex interaction 
with mutated TP5315. he available inhibitor Adavosertib, currently used in several clinical trials in combination 
with other drugs, is reported to be well tolerated, with fatigue, nausea, thrombocytopenia and diarrhea as most 
common adverse events20–22,38. First results as single agent or when used in a combination therapy seem prom-
ising, with an overall response rate of 43% when combined with carboplatin in a phase II study in patients with 
TP53-mutated ovarian cancer20. In a recent neoadjuvant study in HNSCC patients, initial responses when com-
bined with platinum and 5-FU were also promising21.
Here we show that Adavosertib is efective in premalignant cells as well. Hence, Wee1 inhibition monotherapy 
could well serve as chemopreventive strategy to eradicate precancerous changes and prevent cancer and local 
relapse. Importantly, premalignant cells were comparably sensitive to Wee1 inhibition as the fully transformed 
HNSCC cancer cell lines and demonstrated comparable mitotic failures39–41. he chemopreventive potential of 
Wee1 inhibitors could be investigated in patients with an (erythro-)leukoplakia lesion that harbor genetic changes 
such as 3p and 9p losses42. In addition, it could be applied as adjuvant chemopreventive therapy ater surgi-
cal resection in HNSCC patients with dysplastic and genetic changes in the surgical margins to prevent local 
recurrence and second primary tumors5. In a phase I/II study, an intermediate endpoint could be exploited such 
as shrinkage of the lesion with photo-documentation or auto-luorescence, and also by histology and genetic 
changes in biopsies and brushed samples43–45. In a subsequent phase III study, the eicacy in terms of cancer 
prevention could be evaluated as endpoint.
In conclusion, we show that there is a multitude of druggable targets for squamous cancer and premalignant 
cells, despite the fact that HNSCC is a tumor suppressor gene driven disease9. An excellent and promising drug 
target for both the tumors and the precancerous ields is Wee1-like kinase, eiciently targeted by Adavosertib. 
he rewiring of cell cycle control by the frequent inactivation of TP53 and CDKN2A in early carcinogenesis of 
HNSCC, is an excellent approach for targeted treatment of tumors and precancerous mucosal changes.
(h) and D19 (i), and HNSCC cell line UM-SCC-22A (j), ater 24 h treatment with Adavosertib. VU-preSCC-M3 
was pulsed with EdU for 15 min and subsequently the DNA content was stained with DAPI using the Click-IT 
method. All other cell lines (including those shown in Fig. S3e) were pulsed with BrdU for 15 min and DNA 
content was measured using PI. Both precancerous and tumor cells showed aberrant cell cycle distributions.
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Methods
Cell culture. Use of residual tissue samples was carried out according to the guidelines of the Dutch Medical 
Scientiic Societies (www.federa.org). he studies with extra biopsies were approved by the Institutional Review 
Board of Amsterdam UMC, location VUmc and patient specimen were used ater written informed consent. 
Primary cells were collected from excised uvulas of healthy adults as previously described46. he ibroblasts were 
cultured in Dulbecco’s Modiied Eagle’s Medium (DMEM, Lonza, BE12-707F), with 10% fetal bovine serum (FBS, 
Biological Industries, 04-007-1 A) and 2 mmol/L L-glutamine (Lonza, BE17-605F). Primary keratinocytes and 
VU-preSCC-M3 cells were cultured in serum-free KGM medium (KGM-SFM, Gibco, 17005042), supplemented 
with 0.1% BSA (MP Biomedicals, 9048-46-8), 25 mg bovine pituitary extract (Gibco, 17005042), 2.5 µg human 
Figure 4. Efects of Wee1 inhibition on cell cycle regulation, DNA damage and mitosis. (a–d) Western blot 
analysis of premalignant cell lines VU-preSCC-M3 (a) and D19 (b), HNSCC cell line UM-SCC-22A (c) and 
ovarian cell line OVCAR3 (d) all showed decreased p-CDK1 Y15 expression upon treatment with 100 nM 
Adavosertib, already ater 4 h of treatment (c). Increased levels of γH2Ax Ser139 indicated DNA damage 
induced by Wee1 inhibition. Additional cell lines are shown in Fig. S4a–c. (e,f) Precancerous cells VU-
preSCC-M3 (e) and HNSCC UM-SCC-22A (f) were stained for α-tubulin (microtubules, in green) and DNA 
(DAPI, in blue). In untreated conditions, both the premalignant and tumor cell lines showed normal bipolar 
spindle formation with condensated chromosomes. Upon treatment with 100 nM Adavosertib for 48 h, (pro-)
metaphase cells showed less dense spindles with problematic DNA alignment, as well as tripolar spindles and 
micronuclei formation in UM-SCC-22A. Ater treatment with 250 nM Adavosertib, chromosomal alignment 
and condensation was increasingly abnormal in both cell lines and giant cells with multiple nuclei or nuclei 
fragmentation were found, a result of mitotic failure. No monopolar spindles were found. (g,h) To investigate 
mitotic exhaustion due to SAC checkpoint activation, pole-to-pole length (µm) was measured of (pro-)
metaphases in untreated and 100 nM Adavosertib treated cells. A signiicant increase of pole-to-pole length 
was found in both VU-preSCC-M3 (g, two-sided t-test, p = 0.007) and UM-SCC-22A (h, two-sided t-test, 
p = 0.0001) (see Fig, S4d for a representative picture).
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recombinant EGF (Gibco, 17005042), 250 µg Amphotericin B (Gibco, 15290018) and 250 µg Gentamycin (Sigma-
Aldrich, G1397). D4, D19 and D35 were obtained from Prof. K. D. Hunter47,48 and cultured in DMEM supple-
mented with 10% FBS, 2 mmol/L L-Glutamine, 1 × 10−7 M Insulin (Sigma, I9278), 2.5 × 10−4 M Hydrocortisone 
(Sigma, H0888) and 2.5 µg/L EGF (Invitrogen, PHG6045).
FaDu, OVCAR3 and SKOV3 were obtained from the American Type Culture Collection. he other used 
cell lines were obtained and cultured as described before5,12,13,15,49–51. All cells were cultured without antibiotics, 
were mycoplasma negative and checked regularly (Mycoalert, Lonza, LT07-318), and were authenticated by visual 
inspection and genetic proiling on indication. Cell lines were cultured to a maximum of four months ater thaw-
ing. he TP53-mutation status of all precancerous lines and OVCAR3 and SKOV3 were determined as described 
before52.
siRNA re-screen and data analysis. A library of 319 lethal siRNA SMARTpools was custom-made based 
on previous results11. Array-based re-screening of this library and read-out of cell viability was performed in a 
96-wells plate (Greiner-Bio one, 655180) in triplicate for every cell line as described (Table 1)12. he data was Log2 
transformed and normalized for replicate and plate efects per cell line using a linear regression model, based on 
the negative controls present on every plate (siCONTROL#2, Dharmacon, D-001206-14). Median values of the 
triplicates were calculated to determine the efect on viability, providing a viability score for every siRNA tested.
Collateral lethality. Low-coverage whole-genome sequencing of the cell lines was performed as described 
previously5,15. he obtained DNA copy number (CN) data and siRNA viability scores were analyzed using the 
gene-set model approach14. Briely, each CN-variable and viability score of all siRNAs located on the same chro-
mosome arm were associated. his provided a p-value for each CN-variable, subsequently corrected for multiple 
testing using Benjamini-Hochberg’s FDR method53.
siRNA deconvolution. siRNA deconvolution was performed as described (Table S1)12.
ǦǤ 24 h ater seeding cells in a 96-wells microplate in 
a pre-determined conluency, the small molecule Wee1 inhibitor Adavosertib (AZD1775/MK-1775, Biovision, 
2373) or PARP inhibitor Talazoparib (AvonMedchem, Avon2502) was diluted in a serial dilution of 0.8 nM to 
100 µM for tumor cell lines and precancerous cells, and in 0.1 nM to150 µM for primary cells (DMSO < 1%). 
Ater 72 h, cell viability was determined using CellTiter-Blue (Promega, G8080) and a GloMax microplate reader 
(Promega, GM3000). Cells were tested three times in triplicate.
For combination experiments with γ-irradiation, cells were seeded in a 24-wells format at low density, irradi-
ated and treated with the inhibitor 24 h later using a 60Co source (Gammacell 220, MDS Nordion). When wells 
reached 90% conluency at day 9, cells were ixed using 2% paraformaldehyde (Sigma-Aldrich, P6148) for 15 min, 
and stained for 30 min using crystal violet (Sigma-Aldrich, C0775, 1 mg/mL in H2O). Ater drying, crystal violet 
absorbance was obtained by adding 10% acetic acid for 20 min and measuring absorbance at λ590 nm.
Cell cycle analysis. Cells were seeded in a T25 lask and when 50% conluence was reached, treated for 
24 h with Adavosertib. Before harvest, cells were pulsed with 4nmol/L 5-bromo-20-deoxyurdine (BrdU, 
Sigma-Aldrich, 19–160) for 15 min, then harvested and ixed in 75% ice-cold EtOH overnight. Next, cells were 
incubated with 0.5 mg/mL RNAse A, permeabilized with 5 mol/L HCl:0.5% Triton X-100 for 20 min and HCl 
neutralized with 0.1 mol/L Na2B4O7. BrdU was stained overnight at 4 °C with mouse-anti-BrdU antibody (clone 
BU20a, M0744, Dako), and luorescein isothiocyanate (FITC)-labeled with a conjugated rabbit anti-mouse anti-
body (F0313, Dako). DNA content was stained with propidiumiodide (PI) (5 µg PI per 106 cells, Sigma-Aldrich, 
P4170).
For VU-preSCC-M3, the Click-iT™ EdU Alexa Fluor™ 488 Flow Cytometry Assay Kit (ThermoFisher 
Scientific, C10420) was used according to the protocol of the manufacturer, and DNA was stained with 
4′,6-diamidino-2-phenylindole (DAPI).
BD LSR II FortessaTM and BD FACSDivaTM sotware V8.0.1 (BD Biosciences) were used for low cytometry 
and data analysis.
Western blot analysis. Whole cell lysates were obtained by RIPA lysis and extraction bufer (hermo 
Scientific, 89900) containing 1x HALT™ protease and phosphatase inhibitor EDTA-free cocktail (Thermo 
Scientiic, 78441). Protein content was measured with PierceTM BCA Protein assay (hermo Scientiic, 23225). 
Normalized whole cell lysates were run on 4–12% pre-casted gradient SDS-PAGE gels (Bolt Bis-Tris Plus gels, 
Invitrogen, NW04120) using MOPS or MES running bufer. Ater blotting with TG bufer (BioRad, 1610771), 
SuperSignal® West Pico Chemiluminescent Substrate (hermo Scientiic, 34580) was used for development on 
Uvitec 47 Alliance reader (Uvitec Cambridge) or Odyssey® CLx Imaging System (Li-COR). Antibodies used are 
listed in Table S1. All original blots can be found in Fig. S5a,b.
ƪǤ Microscopic glass slides were prepared as described previously11 and pic-
tures were obtained using a Leica DM6000. Analysis and pole-to-pole measurements were performed using LAS 
Application Suite X (version 3.4.2, Leica).
Statistical analysis. All statistical analyses were performed using Graphpad Prism (version 7 and 8) or R 
(version 3.4.3). he statistical package SIM (version 1.48)14 was used for the integrated analysis of the copy num-
ber and siRNA viability score.
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